Videos de Experimentos Relacionados
La cirrosis hepática es una cirrosis hepática
Detlef Schuppan1, Nezam H Afdhal
1Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. dschuppa@bidmc.harvard.edu
Lancet (London, England)
|March 11, 2008
Resumen
La cirrosis, una afección hepática grave, está siendo mejor controlada debido a los avances en la comprensión de su progresión y complicaciones. Los nuevos tratamientos tienen como objetivo detener o revertir la enfermedad hepática, mejorando los resultados de los pacientes más allá del trasplante.
Área de la Ciencia:
- Hepatología Hepatología.
- Medicina interna es la medicina interna de las enfermedades.
- Fisiopatología Fisiopatología.
Sus antecedentes:
- La cirrosis se caracteriza por cicatrización hepática por lesión crónica, lo que lleva a hipertensión portal y enfermedad hepática en etapa terminal.
- La comprensión científica reciente ha mejorado el manejo, la calidad de vida y la supervivencia de los pacientes con cirrosis.
- Si bien el trasplante de hígado es curativo para algunos, están surgiendo nuevos enfoques farmacológicos para detener o revertir la progresión de la enfermedad hepática.
Objetivo del estudio:
- Proporcionar una visión global del diagnóstico, las complicaciones y el manejo de la cirrosis.
- Para resaltar los recientes avances clínicos y científicos en la comprensión y el tratamiento de la cirrosis.
- Para discutir el desarrollo de nuevos tratamientos farmacológicos para la enfermedad hepática.
Principales métodos:
- Revisión de la literatura actual sobre la fisiopatología y la historia natural de la cirrosis.
- Análisis de datos recientes de ensayos clínicos para tratamientos emergentes de cirrosis.
- Síntesis de los conocimientos de expertos sobre el diagnóstico y las estrategias de gestión.
Principales resultados:
- Mejora de los resultados de los pacientes y la esperanza de vida a través de un mejor manejo de las complicaciones de la cirrosis.
- Desarrollo de agentes farmacológicos que muestren potencial para detener o revertir la fibrosis hepática.
- Identificación del trasplante de hígado como una opción curativa clave para pacientes seleccionados.
Conclusiones:
- Los avances en la comprensión de la cirrosis están mejorando la atención y el pronóstico del paciente.
- Los tratamientos farmacológicos están en el horizonte para potencialmente revertir el daño hepático.
- Los enfoques multifacéticos, incluidos el trasplante y las nuevas terapias, son cruciales para el manejo de la enfermedad hepática avanzada.
Videos de Conceptos Relacionados
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:26Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
01:22Portal Hypertension
Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...
01:27Liver Histology
The microscopic anatomy of the liver is a complex and intricate system that comprises numerous structural units known as liver lobules, each of which is comparable in size to a sesame seed. These hexagonal structures consist of plates of liver cells or hepatocytes, which are characterized by their versatility and abundance of cellular apparatus like rough and smooth ER, Golgi apparatus, peroxisomes, and mitochondria.
Hepatocytes perform a variety of essential functions. They secrete...
Hepatocytes perform a variety of essential functions. They secrete...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...